Skip to content
DataLookout
Menu

NCT05887492

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 15 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
    • Study completion pushed from Sep 2026 to Nov 2026
    • Primary completion date changed from estimate of Sep 2026 to Sep 22, 2026
    • Secondary endpoints: details revised at 2 of 8 entries
    • Site details revised at 1 of 13 sites
  2. Notable Primary and study completion dates pushed to Sep 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 13 of 13 sites
    v17
  3. Minor Study sites: 11 to 13v16
  4. Minor Study sites: 10 to 11v15
  5. Notable Primary completion date: Jan 2025 to Jan 2026
    • Study sites: 9 to 10
    • Study completion date: Jun 2025 to Jun 2026
    v13
Show 9 earlier versionsHide 9 earlier versions
  1. Minor Study sites: 8 to 9v11
  2. Minor Study sites: 7 to 8v9
  3. Minor Study sites: 6 to 7v8
  4. Minor Study sites: 5 to 6v7
  5. Minor Study sites: 4 to 5v6
  6. Minor Study sites: 3 to 4v5
  7. Minor Study sites: 2 to 3v4
  8. Minor Study sites: 1 to 2
    • Start date changed from estimate of Jun 2, 2023 to Jun 12, 2023
    v3
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Jul 2023 to Jun 2, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Determine the MTD and RP2D(s) (Phase 1 only)
Timeframe: 42 days
Measure antitumor activity using RECIST 1.1 (Phase 2 only)
Timeframe: 12 weeks

Secondary (8)

Measure antitumor evidence of TNG260 + pembrolizumab antineoplastic activity by RECIST 1.1 (Phase 1 only)
Characterize Area Under the Curve (AUC) of TNG260
Characterize the time to achieve Time to Maximal Concentration (Tmax) of TNG260
Characterize Maximum Observed Plasma Concentration (Cmax) of TNG260
Characterize Terminal Half-life (T1/2) of TNG260
Show 3 moreShow less
Characterize pembrolizumab concentrations when administered with TNG260
Safety and tolerability of TNG260 by CTCAE 5.0
To measure changes in histone acetylation when administered with TNG260

Arms and interventions

Dose EscalationExperimental

Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD

Dose Expansion in NSCLC with KRAS MutationExperimental

Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab

Dose Expansion in NSCLC with KRAS Wild typeExperimental

Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab

Dose Expansion in Advanced or Metastatic Solid TumorsExperimental

Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab

Drugs: TNG260, Pembrolizumab

Sites

13 sites in 1 country